Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), though uncommon, presents a considerable therapeutic challenge with poor long-term outcomes. Currently, tyrosine kinase inhibitors are the mainstay of treatment for advanced RAIR-DTC patients. However, these agents are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Satapathy, Swayamjeet, Bal, Chandrasekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315044/
https://www.ncbi.nlm.nih.gov/pubmed/35903277
http://dx.doi.org/10.3389/fendo.2022.924841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315044/
https://www.ncbi.nlm.nih.gov/pubmed/35903277
http://dx.doi.org/10.3389/fendo.2022.924841

Ejemplares similares